Mar 21 |
Context Therapeutics reports FY results
|
Mar 21 |
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
|
Nov 9 |
Context Therapeutics GAAP EPS of -$0.37 misses by $0.06
|
Nov 9 |
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
|
Oct 31 |
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
|
Oct 24 |
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
|
Oct 2 |
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
|
Sep 27 |
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
|